Table 2 Univariate and multivariate Cox proportional hazards model for overall survival in breast cancer patients (n = 175)
Clinicopathological parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Hazard ratio | CI 95% | P-value | Hazard ratio | CI 95% | P- value | |
Estrogen receptor | ||||||
positive (vs. negative) | 0.737 | 0.285-1.906 | 0.530 | |||
Progesterone receptor | ||||||
positive (vs. negative) | 0.559 | 0.214-1.458 | 0.235 | |||
HER2 | ||||||
positive (vs. negative) | 1.765 | 0.661-4.716 | 0.257 | |||
Hormone receptor | ||||||
positive (vs. negative) | 0.737 | 0.285-1.906 | 0.530 | |||
Age | ||||||
> = 45 (vs. <45) | 1.886 | 0.626-5.684 | 0.260 | |||
Histological grade | ||||||
III (vs. II & I ) | 2.572 | 1.238-5.342 | 0.011 | |||
pT | ||||||
4 & 3 (vs. 2 & 1) | 1.724 | 0.996-2.985 | 0.052 | 1.77 | 1.005-3.118 | 0.048 |
pN | ||||||
positive (vs. negative) | 4.343 | 1.263-14.933 | 0.020 | 4.40 | 1.238-15.673 | 0.022 |
Stage | ||||||
III (vs. II & I ) | 1.985 | 0.878-4.489 | 0.100 | |||
PTPRO methylation | ||||||
methylated (vs. unmethylated) | 3.273 | 0.754-14.209 | 0.113 | |||
PTPRO methylation & HER2 status | ||||||
Methylated/HER2+ (vs. others) | 2.749 | 1.065-7.097 | 0.037 | 3.663 | 1.371-9.784 | 0.010 |